Stay updated with breaking news from Aneck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Slower growth can free room for EM rate cuts and potentially lead to better current account outcomes. Still, EM is not a monolith, and slower growth will pose policy challenges for many.
PFXF is among the assets that that dealt with headwinds in 2022. However, it could turn brighter in 2023 and PFXF has some sources of allure.
Following one of the worst years on record for the fixed income market, bond ETFs are offering investors a variety of rebound opportunities.
Fortunately, ETFs such as PPH feature rosters that are chock full of quality pharmaceutical companies with traits to power 2023 rebounds.
If the Fed dials back the pace of its rate hikes in 2023 and lays off that plan altogether, a preferred ETF or stock could be prime rebound candidates.